Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cimetropium is a semi-synthetic belladonna alkaloid and a quaternary derivative of scopolamine, classified as an antispasmodic and antimuscarinic agent. It acts primarily by binding to muscarinic acetylcholine receptors in the gastrointestinal tract, inhibiting their activity and thereby reducing smooth muscle spasms. This mechanism provides relief from painful gastrointestinal conditions such as irritable bowel syndrome (IBS), abdominal colic (including pediatric use), pyloric spasm, and other spastic manifestations of the GI tract. Cimetropium also has direct myolytic action that contributes to its antispasmodic effects. It has been used under the brand name Alginor in Italy for these indications, including as premedication for diagnostic or operative endoscopy procedures. The drug is not approved in the United States or Canada[1][2][3][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cimetropium.